Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Ramping up production, very positive sign

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Mar 20, 2024 2:36pm

255 Views

Post# 35943359

RE:RE:RE:RE:RE:RE:RE:Ramping up production, very positive sign

Saab made some disparaging remarks re reovirus's effectiveness, which were quoted in a science magazine. As a result of Saab's remarks, the stock lost 10's of millions in market value, even though Saab's remarks were false, management did nothing to counter his comments. It was members of the Yahoo board that eventually approached the science magazine carrying Saabs comments and presented evidence that Saab was off base. The science magazine retracted Saab's comments. However, the damgae had already been done since the market cap had been greatly damaged.

<< Previous

Bullboard Posts

Next >>

Twelve Labs partners with AWS to revolutionize video search with AI